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Membranous nephropathy
PathogenesisWith the discovery of the phospholipase A2 receptor (PLA2R) and
thrombospondin type-1 domain-containing 7A (THSD7A) as target an-
tigens in 80% of patients with primary membranous nephropathy clini-
cal and experimental research as well as patient management can be
better adapted to the pathophysiology of the disease (Beck et al.,
2009; Tomas et al., 2014). This is still not possible in the remaining
20% of patients, in whom no pathogenic antibodies or pathophysiologic
disease mechanisms are known. It is probable, that in these patients
different antibodies and pathophysiologic mechanisms lead to the de-
velopment of membranous nephropathy. In some of those patients an-
other underlying disease may be the ﬁrst step in initiating the disease.
Thus, a better understanding of the pathophysiology is needed. In the
case presented by Buelli et al. the authors investigate possible mecha-
nisms how an underlying disease, in this case IgG4-related disease,
might lead to the development of membranous nephropathy (Buelli
et al., 2015). They show that circulating IgG4 anti-carbonic anhydrase
II antibodies can bind to carbonic anhydrase II on the podocyte surface.
In cultured podocytes, IgG4 leads to a podocytic stress reaction and ex-
ternalization of SOD2 which could serve as neoantigen under in vivo
conditions. Should this hypothesis in fact apply, it could explain another
mechanism of disease induction in human membranous nephropathy.
Furthermore, the presented data in this study support the hypothesis
that neoantigens may develop during the course of membranous ne-
phropathy, which would add to the observations made by Murtas
et al. earlier (Murtas et al., 2012).
The pathophysiology of membranous nephropathy has drawn the
interest of clinical, histological and experimental research over many
years. The potential role of the immune system in the development
of this disease was assumed more than 50 years ago, when IgG wasDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.03.003.
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branous nephropathy (Mellors et al., 1957). Findings in the ratmodel of
Heymann's nephritis further strengthened the hypothesis of membra-
nous nephropathy being an antibody-mediated autoimmune disease
(Heymann et al., 1959). The question which mechanism leads to
subepithelial immune complex formation in humans, whether it is the
re-formation of circulating immune complexes or the in situ formation
by binding of circulating antibodies to a target antigen on the podocyte
surface remained a matter of discussion for many years. A ﬁrst conﬁr-
mation that in situ immune complex formation is induced by binding
of circulating antibodies to a podocytic antigen and leads to the devel-
opment of membranous nephropathy in humans came in 2002
(Debiec et al., 2002). Transplacental transport of antibodies against neu-
tral endopeptidase from themother to the fetus led tomembranous ne-
phropathy in the newborn. However, antibodies to neutral
endopeptidase were not found to be responsible for the initiation of
membranous nephropathy in adults. The major breakthrough in eluci-
dating the pathophysiology of membranous nephropathy came with
the identiﬁcation of the PLA2R as the target antigen in 70% of patients
with membranous nephropathy (Beck et al., 2009). Circulating PLA2R
antibodies bind to the podocytic PLA2R antigen leading to immune de-
posit formation and membranous nephropathy. While conﬁrming the
in situ formation of immune complexes in these patients, these ﬁndings
lead to more questions about the genesis of membranous nephropathy,
most importantly, how the disease develops in PLA2R antibody negative
patients. In some of these patients, THSD7A was identiﬁed as the
podocytic target antigen with circulating antibodies against THSD7A
(Tomas et al., 2014). These ﬁndings show that more than one podocytic
antigen exists, and circulating antibodies against these antigens lead to
membranous nephropathy. It is now clear that membranous nephropa-
thy may have different pathologic backgrounds in individual patients.
The understanding how the disease develops is of outmost impor-
tance in order to develop new, speciﬁc treatment options. This is also
important in patients with membranous nephropathy, who are nega-
tive for PLA2R and THSD7A antibodies. In some cases membranous
nephropathy is associatedwith other diseases; however, the association
of the diseases might be coincidental and even in the cases of “true”
secondary membranous nephropathy, very little data exist on how the
underlying disease leads to formation of immune deposits. The work
of Buelli et al. elucidates a possible mechanism of disease development
in patients with IgG4-related disease and membranous nephropathy.
The hypothesis of the authors suggests a two-step model of disease in-
duction, where an antibody-independent or an antibody-induced
podocytic lesion associated with IgG4-related disease results in the
formation of podocytic neoantigens. These ﬁndings are important inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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should they be conﬁrmed in vivo. First, they shed more light on the re-
lationship of IgG4-related disease to membranous nephropathy, sug-
gesting that the two diseases are not merely coincidental. At the same
time, this work points to another key question in the ﬁeld: what is the
role of these neoantigens in disease development, perpetuation or re-
mission? This is important for patient care, because it may lead to the
development of more speciﬁc treatment options and new biomarkers
for disease activity and treatment response. To conﬁrm such a hypothe-
sis future studies will need to show that circulating antibodies against
SOD2 are in fact present and persist in patients with membranous ne-
phropathy and how they relate to disease activity over time. The clinical
experience of patients with PLA2R-associated membranous nephropathy
already shows that the discovery of this antigen affects patient care
(Hoxha et al., 2014). Further research on the pathomechanisms of mem-
branous nephropathy should thus also focus on the aim to achieve tai-
lored treatment options, addressing the issue of the need of an
immunosuppressive therapy, versus supportive treatment without im-
munosuppression, which still has a number of severe side effects.
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